| Literature DB >> 22028719 |
Elisabetta Costantini1, Massimo Lazzeri, Vittorio Bini, Michele Del Zingaro, Emanuela Frumenzio, Massimo Porena.
Abstract
The aim of this study was to reevaluate and update the followup of a previously published randomized controlled trial (RCT) on the impact of Burch Colposuspension (BC), as an anti-incontinence procedure, in patients with UI and POP, who underwent POP repair. Forty-seven women were randomly assigned to abdominal POP repair and concomitant BC (24 patients; group A) or POP repair alone without any anti-incontinence procedure (23 patients; group B). Median followup was 82 months (range 60-107); from over 47 patients, 30 reached 6-year followup. Two patients were lost at followup. In group A, 2 patients showed a stage I rectocele. In group B, 2 patients had a stage I rectocele and 1 a stage II rectocele. In group A, 13/23 (56.5%) were still incontinent after surgery compared with 9/22 patients (40.9%) in group B (P = 0.298). No significant changes were observed between the first and the current followup. The update of long-term followup confirmed that BC did not improve outcome significantly in incontinent women when they undergo POP repair.Entities:
Year: 2011 PMID: 22028719 PMCID: PMC3199042 DOI: 10.1155/2012/967923
Source DB: PubMed Journal: Obstet Gynecol Int ISSN: 1687-9597
Demographic and clinical variables of groups A and B. Patient data.
| Colposuspension | Yes (24 patients) | No (23 patients) |
|
|---|---|---|---|
| Age (years; mean/range) | 60.0 ± 10.6 (35.1–79.0) | 62.6 ± 12.8 (26.9–76.4) | NS |
| Menopause ( | 18 (75.0) | 18(78.3) | NS |
| Previous urogynecological surgery | 5 (20.8) | 9 (39.1) | NS |
| Hysterectomy | 5 (20.8) | 8 (34.8) | NS |
| Prolapse repair | 4 (16.7) | 5 (21.7) | NS |
| SUI surgery | 0 (0.0) | 2 (8.7) | NS |
| BMI (kg/m2, median/range) | 25.6 (20.8–35.2) | 27.0 (16.0–31.9) | NS |
| Parity (median/range) | 2 (0–3) | 2 (1–3) | NS |
| ureterocele stage I | 1 (4.2) | 4 (17.4) | NS |
| ureterocele stage II | 6 (25.0) | 8 (34.8) | |
| ureterocele stage III | 17 (70.8) | 11 (47.8) | |
| Heart diseases ( | 2 (8.3) | 1 (4.3) | NS |
| Hypertension ( | 6 (25.0) | 8 (34.8) | NS |
| Hypercholesterolemy ( | 4 (16.7) | 6 (26.1) | NS |
| Lower limb varices ( | 6 (25.0) | 3 (13.0) | NS |
| COPD ( | 1 (4.2) | 2 (8.7) | NS |
| Auto-immune disease ( | 2 (8.3) | 3 (13.0) | NS |
| Anxiety ( | 5 (20.8) | 6 (26.1) | NS |
| Diabetes mellitus type 2 ( | 2 (8.3) | 3 (13.0) | NS |
| Recurrent urinary tract infections | 2 (8.3) | 3 (13.0) | NS |
| Hypothyroidism ( | 1 (4.2) | 2 (8.7) | NS |
| Hydronephrosis ( | 1 (4.2) | 0 (0.0) | NS |
Incontinence, voiding, and storage symptoms: long-term followup in groups A and B. Mid- and long-term outcomes.
| Group A | Group B | |||||||
|---|---|---|---|---|---|---|---|---|
| Previous followup: 50 months | Extended followup: 69 months | Treatment | Results | Previous followup: 46 months | Extended followup: 63 months | Treatment | Results | |
| Incontinent patients | 13/24 | 13/23 | 9/23 | 9/22 | ||||
| 8 SUI | 7 SUI | 9 SUI | 6 SUI | |||||
| 4 MUI | 4 MUI | 3 MUI | ||||||
| 1 UUI | 2 UUI | |||||||
|
| ||||||||
| Grade 1 UI |
|
| 2 FKT (PFME) | Satisfied |
|
| 3 no treatment | Satisfied |
| 4 no treatment | Satisfied with 1/pad die | 1 antimuscarinic agents | Satisfied | |||||
|
| ||||||||
| Grade 2/3 UI |
|
| 4 MUS | Dry |
|
| 2 MUS | Dry |
| 1 refused surgery | Not satisfied | 3 refuse surgery | Not satisfied | |||||
| 2 antimuscarinic agents | Improved | |||||||
|
| ||||||||
| Voiding symptoms | Cured 17/17 | Cured 16/17 | No treatment | Cured 19/21 | Cured 18/20 | No treatment | ||
| Improved 2 | Improved 2 | |||||||
|
| ||||||||
| Cured 12/16 | Cured 10/15 | Cured 15/17 | Cured 14/16 | |||||
| Storage symptoms | Persistent 4 | Persistent 5 | 2 antimuscarinic agents | Improved | Persistent 2 | Persistent 3 | 2 antimuscarinic agents | Improved |
|
|
|
|
| |||||
Secondary outcome end-points in patients of group A and B. Outcomes after mid- and long-term followups.
| Yes colposuspension (group A) | No colposuspension (group B) | Pre | Post | |||||
|---|---|---|---|---|---|---|---|---|
| Before (24) |
| After (23) | Before (23) |
| After (22) | A versus B group | A versus B group | |
| Anatomical Results | 24 | <0.001 | 2 | 23 | <0.001 | 3 | ||
| 2 stage I rectoceles | 2 stage I rectoceles | — | NS | |||||
| 1 Stage II rectocele | ||||||||
| No sexual intercourse | 5 | NS | 7 | 10 | NS | 9 | NS | NS |
| Disturbances during sexual intercourse | 10 | 0.023 | 3 | 8 | NS | 4 | NS | NS |
| No disturbances during sexual intercourse | 9 | NS | 13 | 5 | NS | 9 | NS | NS |
| Constipation | 11 | 0.046 | 3 persistent | 9 | NS | 2 persistent | NS | NS |
| 1 | 1 | |||||||
| IIQ7 (median/range) | 16 (3–35) | <0.001 | 1 (0–11) | 18 (1–45) | <0.001 | 2 (0–17) | NS | NS |
| UDI6 (median/range) | 16 (6–45) | <0.001 | 3 (0–10) | 16 (0–43) | <0.001 | 2.5 (0–14) | NS | NS |
| VAS (median/range) | 8 (4–10) | 8.5 (5–10) | NS | |||||
| Patients would not repeat surgery | 3 | 3 | NS | |||||
| Re-interventions for UI | 4(MUS) | 2 (MUS) | NS | |||||
VAS: Visual Analogue Scale.
MUS: Mediourethral sling.